Starting Glucagon-Like Peptide 1 Treatment in Heart Failure Patients with Weak Heart Pumping and Implanted Heart Devices

Funding Support and Author Disclosures Dr Marques has received salary support by an educational grant from Janssen. Dr Neves has received consulting and speaker fees from AstraZeneca, BIAL, Boehringer Ingelheim, Lilly, Merck, and Novo Nordisk. Dr Tsoukas has received personal fees from Boehringer Ingelheim, AstraZeneca, Janssen, Novo Nordisk, and Eli Lilly. Dr Mavrakanas has received speaker honoraria from Daiichi Sankyo, BMS Canada, Janssen, AstraZeneca, and Pfizer, has served on advisory boards for Boehringer Ingelheim, Bayer, GlaxoSmithKline, and Servier, has received an unrestricted research grant from AstraZeneca and operational grants from the Kidney Foundation of Canada, the Heart and Stroke foundation of Canada, and the Canadian Institute of Health Research, is receiving salary support from the Fonds de Recherche Quebec Santé (Junior 1 Clinician Scholar Award number 298742), and is supported by a Krescent New Investigator Award. Dr Joza has received an investigator-initiated external research program grant from Medtronic and honoraria from Boston Scientific and Medtronic. Dr Ferreira has received research support from AstraZeneca, Boehringer Ingelheim, Novartis, Amgen, Salamandra, and Bial. Dr Sharma has received support from the Fonds de Recherche Santé Quebec Junior 1 clinician scholars’ program and the Canadian Institute of Health Research (grant number 175095), and research, grant, or consultation support from Roche Diagnostics, Boehringer Ingelheim, Novartis, Janssen, Novo Nordisk, Servier, AstraZeneca, Bayer, Vifor, and Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.